Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 91 clinical trials
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide Aldesleukin and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

This phase Ib trial studies the side effects and best dose of autologous CD8 positive (+) SLC45A2-specific T lymphocytes when given together with cyclophosphamide, aldesleukin, and ipilimumab, and to see how well they work in treating patients with uveal melanoma that has spread to other places in the body (metastatic). …

metastasis
interleukin-2
measurable disease
mitomycin
cancer
  • 30 views
  • 27 Jan, 2021
  • 2 locations
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

This phase I clinical trial evaluates the safety and feasibility of administering NY-ESO-1 TCR (T cell receptor)engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem cells (PBSC) after a myeloablative conditioning regimen to treat patients with cancer that has spread to other parts of the body. The conditioning chemotherapy …

advanced cancer
measurable disease
ct scan
solid tumors
metastatic cancer
  • 7 views
  • 21 Mar, 2021
  • 1 location
RTX-321 Monotherapy in Patients With HPV 16+ Tumors

This is an open-label, multicenter, multiple-ascending dose, FIH, Phase 1 study of RTX-321 for the treatment of patients that are HLA-A*02:01 positive with persistent, recurrent, or metastatic

neutrophil count
mitomycin
growth factor
mitomycin c
human papilloma virus vaccine
  • 0 views
  • 30 Aug, 2021
  • 7 locations
SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

This is a study to investigate the efficacy and safety of ADP-A2M4 in combination with pembrolizumab in HLA-A*02 eligible and MAGE-A4 positive subjects with recurrent or metastatic Head and Neck

squamous cell carcinoma
metastatic head and neck cancer
squamous cell carcinoma of head and neck
measurable disease
pembrolizumab
  • 0 views
  • 12 Sep, 2021
  • 5 locations
TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms

, persistently transduced with a Preferentially Expressed Antigen in Melanoma (PRAME)-specific human leukocyte antigen (HLA)-A*02:01-restricted T cell receptor (TCR).

  • 3 views
  • 23 Jan, 2021
  • 10 locations
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)

Leukocyte Antigen (HLA) A-2-positive advanced hepatocellular carcinoma (HCC).

neutrophil count
measurable disease
line of therapy
alpha fetoprotein
carcinoma
  • 30 views
  • 04 Jun, 2021
  • 4 locations
Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation

matching will include matching of 2 HLA antigens that can be either HLA A, B, and /or DR. This research will change the immune system such that immunosuppressive drugs can be completely withdrawn or

  • 43 views
  • 25 Jan, 2021
  • 2 locations
Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

and HLA-A*11:01 allele. The theoretical basis of this study is that mutant KRAS antigen-specific TCR transduced autologous Tcells will target and kill HLA-matched mutant KRAS cancer cells but not

EGFR
neutrophil count
hepatitis b surface antigen
KRAS
cancer
  • 4 views
  • 24 May, 2021
  • 1 location
TAEST16001 in the Treatment of Soft Tissue Sarcoma

sarcoma whose tumor antigen NY-ESO-1 expression is positive (HLA-A * 02:01).

neutrophil count
ifosfamide
measurable disease
carboplatin
doxorubicin
  • 0 views
  • 25 Jan, 2021
  • 1 location
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

This phase I trial studies the side effects and best dose of CD4+ and CD8+ HA-1 T cell receptor (TCR) (HA-1 T TCR) T cells in treating patients with acute leukemia that persists, has come back (recurrent) or does not respond to treatment (refractory) following donor stem cell transplant. T …

hla-a
juvenile myelomonocytic leukemia
stem cell transplantation
blast cells
tyrosine
  • 71 views
  • 16 Jul, 2021
  • 1 location